Not exact matches
Although treatment for sickle -
cell disease with marrow from related
donors is now accepted as a standard of care, treatment with marrow taken from an
unrelated donor is still evolving, reserved for only the most seriously sick patients.
To assess risk, Thomas Adamkiewicz, codirector of the Hemoglobinopathy / Genomics Training Program at Morehouse School of Medicine in Atlanta, surveyed four medical centers and found that seven children with sickle -
cell disease had been treated with umbilical cord blood from
unrelated donors.
Ildstad and her colleagues report that five of eight people who underwent the treatment were able to stop all immunosuppressive therapy within a year after their kidney and stem -
cell transplants, four of which came from
unrelated donors.
Abatacept, when added to the standard drug regimen used to prevent GvHD, reduced the occurrence of acute, grade III - IV GvHD from 32 to 3 percent in pediatric and adult patients who underwent mismatched
unrelated donor stem
cell transplants to treat advanced cancer and other blood disorders.
Now, researchers have for the first time managed to completely replace people's bone - marrow - derived stem
cells with those from
unrelated donors without causing GvHD.
Concerned that the drug by itself might not keep his aggressive cancer at bay, Wartman opted for a second transplant — this time with stem
cells isolated from peripheral blood from an
unrelated donor.
Each patient then received a kidney from a genetically mismatched relative or
unrelated donor; the concoction of
donor cells processed by Ildstad's team was given a day later.
Use of a lower dose of rabbit anti — T - lymphocyte globulin (ATLG) was superior to a higher dose in children with hematologic malignancies undergoing allogeneic hematopoietic stem
cell transplantation (HSCT) from an
unrelated donor, according to the results of a study published in Lancet Oncology.
Xenogeneic
cells obtained from a
donor organism of an
unrelated species.
Patients transplanted with
cells from a parent or an
unrelated donor do not do as well as those receiving fully matched transplants.
Patients receive one of two types of stem
cell - based transplants: autologous, in which a patient donates and receives back his / her own stem
cells; or allogeneic, in which bone marrow - derived stem
cells come from a related or
unrelated donor whose human leukocyte antigens (HLA) are genetically matched with those of a patient.
Another study is testing whether
unrelated donor stem
cell transplant can provide better long - term outcomes than traditional immunosuppressive therapy (IST) for children with severe aplastic anemia.
Low - Dose ATLG Prevents GVHD in Pediatric Hematologic Malignancies: A newly published randomized phase III study of pediatric patients showed lower doses of rabbit anti — T - lymphocyte globulin (ATLG) was superior to a higher dose in children with hematologic malignancies undergoing allogeneic hematopoietic stem
cell transplantation from an
unrelated donor.
It offers to the commercialization of
unrelated donor - patient (allogeneic)
cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders.